Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Praxis Precision Medicines, Inc.

NASDAQ: PRAX · Life Sciences · 3 alerts · CIK 1689548

Share price
$310.27Close, Nov 16
Market cap
$8.67B
Shares outstanding
27.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Praxis Precision Medicines, Inc. filings on SEC EDGAR ↗

5:02 PM ET 8-K
Investor Presentation

Praxis Precision Medicines Investor Presentation

Praxis Precision Medicines hosted an Investor Day in New York City to detail its commercial strategy and launch plans for ulixacaltamide in essential tremor and relutrigine in DEEs. The company also provided an expanded pipeline update, including plans to initiate studies for ulixacaltamide in Parkinson’s disease and autism spectrum disorder in 2027.

4:33 PM ET 10-Q
Financial Results

Praxis Precision Medicines Q3 2026 Results: Net Loss of $94.2M, Loss Widens

Praxis Precision Medicines reported a net loss of $94.2 million for the third quarter of 2026, compared to $73.9 million in the prior year period, driven by increased general and administrative expenses. The company significantly strengthened its balance sheet through a follow-on public offering, ending September 30, 2026, with $1.31 billion in total assets including $745.3 million in cash and marketable securities.

Key figure
Net loss $94.2M
7:03 AM ET 8-K
Financial Results

Praxis Precision Medicines Financial Results

Praxis Precision Medicines reported third quarter 2026 financial results, highlighting a strong cash position of $1.3 billion to support operations into 2028. The company is preparing for two potential commercial launches with FDA PDUFA dates for relutrigine on December 27, 2026, and ulixacaltamide on January 29, 2027. Management is currently hiring a field sales force and expects topline results from the EMERALD study in the fourth quarter of 2026.

Term
Q3 2026

“We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a commercial CNS company. Our teams are working to bring relutrigine and ulixacaltamide to patients who need new options. The relutrigine team is fully hired, and we expect the ulixacaltamide sales force to be in place this quarter. We continue to advance our broader pipeline, with EMERALD and EMBRAVE3 progressing toward important readouts. We look forward to discussing our commercial strategies, launch readiness and pipeline at our Investor Day later this week.”

Marcio Souza, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.